Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | TPMT | P51580 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30278904 | 0.85 | HTT (0.71) | MAPK1CYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL1477740 | 0.85 | HTT (0.71) | MAPK1CYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL28094523 | 0.85 | CYP1A2 (0.68) | MAPK1CYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL335681 | 0.84 | MAPK1 (0.77) | MAPK1CYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL29415167 | 0.84 | MAPK1 (0.77) | MAPK1CYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL30307554 | 0.83 | HTT (0.73) | MAPK1CYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL29599043 | 0.83 | LMNA (0.55) | MAPK1CYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL156299 | 0.83 | HTT (0.73) | MAPK1CYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL660929 | 0.83 | LMNA (0.55) | MAPK1CYP1A2TSHRCYP3A4CYP2C19 | |
| SCHEMBL23850758 | 0.83 | CYP1A2 (0.47) | MAPK1CYP1A2TSHRCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696611-B2 | Adamantane derivative compound | AMOREPACIFIC CORPORATION (KR) | 2020-06-30 | — | — | US | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| US-20170283347-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2017-10-05 | — | — | US | claimed |
| EP-3187486-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | Amorepacific Corporation (KR) | 2017-07-05 | — | — | EP | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-3187486-B1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | AMOREPACIFIC CORP (KR) | 2023-10-18 | — | — | EP | disclosed |
| US-10696611-B2 | Adamantane derivative compound | AMOREPACIFIC CORPORATION (KR) | 2020-06-30 | — | — | US | disclosed |
| CN-107207416-B | Novel adamantane derivative compound | 株式会社爱茉莉太平洋 | 2020-02-07 | — | — | CN | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-1911743-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911743-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696611-B2 | Adamantane derivative compound | ADAM8, BACE1, CYP17A1 | MAPK1 2937/4885CYP1A2 287/4885TSHR 4090/4885 |
| US-20170283347-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | ADAM8, CYP17A1, ADAM10 | MAPK1 2795/4885CYP1A2 333/4885TSHR 3845/4885 |
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | ERBB2, ERBB3, ARRB1 | MAPK1 80/4885CYP1A2 2879/4885TSHR 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.